# Mineralocorticoid Receptor Antagonists in End Stage Renal Disease

> **NCT01691053** · PHASE2 · COMPLETED · sponsor: **Wuerzburg University Hospital** · enrollment: 118 (actual)

## Conditions studied

- End Stage Renal Disease / Hemodialysis

## Interventions

- **DRUG:** Spironolactone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01691053
- **Lead sponsor:** Wuerzburg University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2017-02-14
- **Final completion:** 2018-03-28
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2019-08-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01691053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01691053, "Mineralocorticoid Receptor Antagonists in End Stage Renal Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01691053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*